David Nierengarten
Stock Analyst at Wedbush
(3.57)
# 831
Out of 4,876 analysts
218
Total ratings
42.13%
Success rate
7.26%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Reiterates: Neutral | $0.4 | $1.06 | -62.26% | 8 | Jun 26, 2025 | |
| ARGX argenx SE | Reiterates: Outperform | $715 | $562.31 | +27.15% | 21 | Jun 24, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $3.60 | +205.56% | 4 | Jun 23, 2025 | |
| TLX Telix Pharmaceuticals | Reiterates: Outperform | $22 | $16.09 | +36.73% | 2 | Jun 12, 2025 | |
| NUVB Nuvation Bio | Maintains: Outperform | $5 | $1.97 | +153.81% | 9 | Jun 11, 2025 | |
| BPMC Blueprint Medicines | Downgrades: Neutral | $128 → $129 | $128.21 | +0.62% | 5 | Jun 2, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Neutral | $10 → $12 | $10.00 | +20.00% | 3 | May 28, 2025 | |
| NTLA Intellia Therapeutics | Reiterates: Neutral | $10 | $9.76 | +2.46% | 9 | May 19, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $29 → $27 | $17.28 | +56.25% | 8 | Apr 16, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Reiterates: Outperform | $34 | $28.48 | +19.38% | 3 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $8.86 | +272.46% | 6 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $0.79 | +152.18% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.08 | +365.12% | 15 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $8.82 | +251.47% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $46.99 | +63.86% | 6 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $23.02 | +73.76% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $43.38 | +107.47% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $35.60 | +32.02% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $4.00 | +275.00% | 6 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $99 → $115 | $79.34 | +44.95% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $4.71 | +388.36% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $10.37 | +92.86% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $11.20 | +257.14% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $15.70 | +186.62% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.48 | +575.68% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $1.59 | +1,032.08% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $54.32 | +4.94% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.35 | +1,318.44% | 8 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.33 | +50.38% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $7.31 | +36.80% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $36 | $8.27 | +335.31% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $2.54 | +373.37% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $17.08 | +233.72% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $7 | $0.32 | +2,087.50% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $3.03 | +16,428.93% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $4.55 | +1,218.68% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $8.37 | +127.00% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $36.55 | +105.20% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.06 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.92 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.24 | - | 3 | Nov 20, 2017 |
Vor Biopharma
Jun 26, 2025
Reiterates: Neutral
Price Target: $0.4
Current: $1.06
Upside: -62.26%
argenx SE
Jun 24, 2025
Reiterates: Outperform
Price Target: $715
Current: $562.31
Upside: +27.15%
Perspective Therapeutics
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $3.60
Upside: +205.56%
Telix Pharmaceuticals
Jun 12, 2025
Reiterates: Outperform
Price Target: $22
Current: $16.09
Upside: +36.73%
Nuvation Bio
Jun 11, 2025
Maintains: Outperform
Price Target: $5
Current: $1.97
Upside: +153.81%
Blueprint Medicines
Jun 2, 2025
Downgrades: Neutral
Price Target: $128 → $129
Current: $128.21
Upside: +0.62%
iTeos Therapeutics
May 28, 2025
Downgrades: Neutral
Price Target: $10 → $12
Current: $10.00
Upside: +20.00%
Intellia Therapeutics
May 19, 2025
Reiterates: Neutral
Price Target: $10
Current: $9.76
Upside: +2.46%
NovoCure
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $17.28
Upside: +56.25%
Kiniksa Pharmaceuticals International,
Apr 16, 2025
Reiterates: Outperform
Price Target: $34
Current: $28.48
Upside: +19.38%
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $8.86
Upside: +272.46%
Mar 14, 2025
Downgrades: Neutral
Price Target: $8 → $2
Current: $0.79
Upside: +152.18%
Mar 6, 2025
Reiterates: Neutral
Price Target: $5
Current: $1.08
Upside: +365.12%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $8.82
Upside: +251.47%
Feb 12, 2025
Reiterates: Outperform
Price Target: $77
Current: $46.99
Upside: +63.86%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $23.02
Upside: +73.76%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $43.38
Upside: +107.47%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $35.60
Upside: +32.02%
Sep 30, 2024
Reiterates: Outperform
Price Target: $15
Current: $4.00
Upside: +275.00%
Sep 16, 2024
Maintains: Outperform
Price Target: $99 → $115
Current: $79.34
Upside: +44.95%
Sep 10, 2024
Reiterates: Outperform
Price Target: $23
Current: $4.71
Upside: +388.36%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $10.37
Upside: +92.86%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $11.20
Upside: +257.14%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $15.70
Upside: +186.62%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.48
Upside: +575.68%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $1.59
Upside: +1,032.08%
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $54.32
Upside: +4.94%
Aug 8, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.35
Upside: +1,318.44%
May 29, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.33
Upside: +50.38%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $7.31
Upside: +36.80%
May 10, 2024
Maintains: Outperform
Price Target: $34 → $36
Current: $8.27
Upside: +335.31%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $2.54
Upside: +373.37%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $17.08
Upside: +233.72%
Feb 29, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $0.32
Upside: +2,087.50%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $3.03
Upside: +16,428.93%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $4.55
Upside: +1,218.68%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $8.37
Upside: +127.00%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $36.55
Upside: +105.20%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.06
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $2.92
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $6.24
Upside: -